An open randomized clinical trial in comparing two artesunate-based combination treatments on Plasmodium falciparum malaria in Nigerian children: artesunate/sulphamethoxypyrazine/pyrimethamine (fixed dose over 24 hours) versus artesunate/amodiaquine (fixed dose over 48 hours)
2010

Comparing Two Treatments for Malaria in Nigerian Children

Sample size: 500 publication 10 minutes Evidence: moderate

Author Information

Author(s): Ayede Idowu Adejumoke, Falade Adegoke Gbadegesin, Sowunmi Akintunde, Jansen Frans Herwig

Primary Institution: University College Hospital, Ibadan, Nigeria

Hypothesis

Is the efficacy of artesunate/sulphamethoxypyrazine/pyrimethamine (AS + SMP) similar to that of artesunate/amodiaquine (AS + AQ) for treating uncomplicated Plasmodium falciparum malaria in children?

Conclusion

Both AS + SMP and AS + AQ are similarly effective and safe for treating uncomplicated malaria in Nigerian children.

Supporting Evidence

  • The PCR corrected cure rates for day 28 were 97.9% for AS + AQ and 95.6% for AS + SMP.
  • The re-infection rate was significantly lower in the AS + AQ group compared to the AS + SMP group.
  • Both treatments were well tolerated with no serious adverse events reported.

Takeaway

This study tested two malaria treatments in kids and found that both worked well and were safe.

Methodology

A randomized, controlled, open-label trial with 500 children aged 1-13 years, comparing two treatment regimens over 28 days.

Potential Biases

Possible bias due to loss to follow-up and differences in demographic characteristics between treatment groups.

Limitations

Loss to follow-up and potential biases in treatment assignment.

Participant Demographics

Children aged 1 to 13 years, with a mix of sexes and varying weights.

Statistical Information

P-Value

0.021

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1475-2875-9-378

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication